Neuboron Medical Group

What Neuboron Medical Group does

Neuboron Medical Group, founded in 2014 and headquartered in Nanjing, China, is a privately held medical technology company that develops and supplies accelerator-based Boron Neutron Capture Therapy (AB-BNCT) systems for treating recurrent and refractory cancers. Its vertically integrated product stack centers on the NeuPex AB-BNCT system — a compact electrostatic accelerator (2.5 MeV / 10 mA) coupled to a proprietary double-cone Beam Shaping Assembly that produces epithermal neutron beams with an advantage depth greater than 11 cm and suprathermal neutron flux exceeding IAEA recommended standards. The stack is completed by the NeuManta Treatment Planning System (with a proprietary Monte Carlo dose engine called COMPASS that runs 150% faster than MCNP6), a 7-axis robotic patient positioning system, patented radiation shielding materials, on-line beam monitoring, and two boron drugs — therapeutic Borofalan(10B) for Injection (NBB-001/BPA) and the world's first registered BNCT companion diagnostic 18F-BPA (NBB-002) for PET imaging.

The company operates a drug-device combined model targeting Class III hospitals and cancer treatment centers seeking complete turnkey BNCT solutions. Commercial revenue has not yet commenced because neither the NeuPex system nor the boron drugs have received NMPA marketing authorization; the company is currently in registered clinical trial stage, with the first drug-device combined Phase I trial launched in April 2024 at the Xiamen Humanity Hospital BNCT Center (China's first and largest AB-BNCT clinical demonstration center, built jointly with Xiamen Humanity Hospital from 2019 and operational since 2021). Revenue streams planned for commercialization include hardware system sales, boron drug sales, technical services and training, and BNCT center facility design and construction. Distribution is via direct enterprise field sales to hospital customers, supplemented by international partnerships in Italy, Southeast Asia, and Latin America.

The company is led by founder/CEO and Chief Scientist Prof. Liu Yuan-Hao (nearly 20 years of BNCT experience, ISNCT Executive Board member, leader of China's National Key Research Program on BNCT) and co-founder Chih Chen (former GE vice president), with approximately 70 R&D-oriented employees. Neuboron holds over 500 granted patents globally across China, the US, Europe, Japan, and Russia, and ranks first worldwide in BNCT patent strength. The company has secured one disclosed minority equity investment of approximately USD 10 million from TAE Life Sciences (December 2020) to form a joint venture for global NeuPex deployment, and operates subsidiaries including Neuboron Therapy System (NTS) and Neuboron Shanghai Technologies.

Name

Neuboron Medical Group

Legal name

Neuboron Medtech Ltd.

Website

https://en.neuboron.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Neuboron Medical Group, founded in 2014 in Nanjing, China, is the world's only vertically integrated provider of accelerator-based Boron Neutron Capture Therapy (BNCT) systems, supplying hospitals with the NeuPex neutron source, NeuManta treatment planning software, and boron drugs (BPA and 18F-BPA) for treating recurrent head, neck, and brain cancers.

Ownership category

akta.pro rank

Product category

Radiation Therapy Equipment

NAICS

Diagnostic Imaging Centers (621512)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Boron neutron capture therapy
• Radiation oncology systems
• Accelerator-based BNCT
• Treatment planning software
• Boron-containing pharmaceuticals

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. BNCT System Equipment Sales: Sale of accelerator-based BNCT systems (NeuPex) to hospital BNCT centers. Neuboron provides complete in-hospital BNCT center solutions including hardware systems, treatment planning software, facility design, and technical services. The system is a Class III medical device requiring NMPA registration before commercial sale.
2. Boron Drug Sales: Targeted boron drugs (therapeutic BPA and companion diagnostic 18F-BPA) sold alongside BNCT systems for clinical use. Drug-device combined products for registered clinical trials and eventual commercial distribution.
3. Technical Services & Support: Professional BNCT team providing clinical support, installation, commissioning, training, and ongoing technical services for hospital BNCT center operations.
4. BNCT Center Design & Construction: Neuboron provides complete facility design, planning, and construction oversight for hospital BNCT centers, integrated with its equipment and software solutions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Neuboron Medical Group develops, manufactures, and supplies a complete accelerator-based Boron Neutron Capture Therapy (AB-BNCT) total solution for hospital cancer treatment centers. Its portfolio spans the NeuPex compact accelerator neutron source system, the NeuManta treatment planning software with proprietary Monte Carlo dose engine, therapeutic boron drug Borofalan (BPA, NBB-001), PET companion diagnostic 18F-BPA (NBB-002), and accompanying technical services, facility design, and clinical support enabling turnkey in-hospital BNCT centers.

Product overview

Neuboron Medical Group offers a comprehensive, integrated BNCT (Boron Neutron Capture Therapy) total solution for hospital users. The portfolio consists of the NeuPex AB-BNCT system (compact accelerator-based neutron source with Beam Shaping Assembly, beam monitoring, and patient positioning), paired with the NeuManta Treatment Planning System (featuring COMPASS Monte Carlo dose engine for dose calculation), targeted boron drugs including therapeutic drug BPA (NBB-001) and companion diagnostic 18F-BPA (NBB-002), plus radiation safety systems and technical services. This drug-device combined approach provides hospitals with a complete in-patient BNCT center solution.

Differentiator

Problem solved

Functional benefit

Products and services

• NeuPex (NeuPEX) AB-BNCT System Compact accelerator-based Boron Neutron Capture Therapy system producing high-quality stable epithermal neutron beams for clinical cancer treatment, featuring 2.5 MeV / 10 mA electrostatic accelerator, double-cone Beam Shaping Assembly with advantage depth >11 cm, 7-axis robotic sub-millimeter patient positioning, on-line beam monitoring, and patented radiation shielding. Configurable for single or multiple treatment rooms. Sold as a turnkey BNCT center package to Class III hospitals.
• NeuManta Treatment Planning System (TPS) BNCT-specific treatment planning software with built-in COMPASS Monte Carlo dose engine, DICOM-RT compatible, supporting CT, PET, and MRI image import; HU-value voxel material conversion for up to 96 materials; automatic dose calculation and visualization; biological equivalent dose computation. Calculation speed reported as 150% faster than MCNP6 with equivalent accuracy. Sold to hospital BNCT centers as part of the NeuPex system or as a standalone planning tool.
• Borofalan (10B) for Injection (BPA / NBB-001) Broad-spectrum boron-containing therapeutic drug transported into tumor cells via the L-amino acid transport system (LAT-1), lyophilized for individualized clinical dosing. Indicated for treatment of recurrent malignant head and neck tumors and gliomas. Demonstrated tumor inhibition rate above 85% in non-clinical head and neck cancer and glioma models. Used in combination with the NeuPex AB-BNCT system as a drug-device combination product.
• NBB-002 (18F-BPA) PET Companion Diagnostic Fluorine-18 labeled PET companion diagnostic used to image LAT-1 expression in solid tumors, enabling patient enrollment screening, treatment planning, individualized dose calculation, efficacy evaluation, and follow-up tracking for BNCT. Used alongside Borofalan (BPA / NBB-001) and the NeuPex system as part of Neuboron's drug-device combination.
• BNCT Technical Services Professional services covering BNCT center planning and facility design, accelerator system installation and commissioning, clinical application training for medical staff, ongoing technical support, and clinical research collaboration. Provided to hospital customers building or operating BNCT centers, including Xiamen Humanity Hospital, Chaoshan Hecheng Hospital, Dongguan People's Hospital, Shanghai Renji Hospital, and international partners such as the University of Campania Caserta BNCT project in Italy.

Quantifiable outcome

• Supratheramal neutron flux of 1.1×10^9 n/cm2/s exceeds IAEA recommended standards at beam exit
• +7 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Partnerships

19 partnerships are on record, tiered core, minor and flagship.

• Chaoshan Hecheng HospitalcoreStrategic or Co-development Partner · 12 January 2025BNCT technology cooperation agreement signed January 2025 covering equipment procurement, BNCT center preparation, clinical registration, technical support, and operation cooperation. First BNCT technology in eastern Guangdong. Hospital to open February 2026.
• Shanghai Lingang Digital SeacoreStrategic or Co-development Partner · 4 July 2024Strategic cooperation agreement signed July 2024 to build world-class BNCT industrial cluster in Digital Sea precision medicine park. Lingang Group and Fengxian District provide full support for Neuboron BNCT industry development. Strategic agreement includes 4 timelines and 21 work items.
• Caserta BNCT Center (Italy - University of Campania)coreStrategic or Co-development Partner · 15 August 2023Italy's first government-backed AB-BNCT project 'BNCT project ANTHEM' led by University of Campania. Neuboron provides guidance on construction and shares NeuPex technology and XHH BNCT Center experience. Part of Sino-Italian international cooperation.
• Argentine National Atomic Energy CommissionminorStrategic or Co-development Partner · 18 July 2023International BNCT collaboration. Prof. Sara González visited XHH BNCT Center and expressed interest in cooperating with Chinese and Italian teams to build accelerator-based BNCT facilities in Argentina.
• Sichuan University (West China Hospital)coreStrategic or Co-development Partner · 1 January 2023Strategic cooperation signed November 2023 to jointly develop BNCT nanomedicines with higher targeting, better intratumoral distribution, and visualization function. Leverages Sichuan University's National Key Laboratory of Biomedical Therapy and Neuboron's NeuPEX system. LA-BPA derivative research for pancreatic cancer BNCT conducted jointly.
• Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyminorStrategic or Co-development Partner · 1 January 2023Director Zhu Xiaohua collaborated with Neuboron on NBB-002 preclinical research, obtaining early safety data and preliminary research data.
• National Institute for Radiological Protection (NIRP), Chinese CDCcoreStrategic or Co-development Partner · 10 November 2021Four-party strategic partnership signed with NIRP, Fujian Center for Prevention and Control of Occupational Diseases, and XHH to accelerate BNCT clinical application, quality control, standardization, and development of clinical guidelines.
• Wuesthoff & WuesthoffminorOthers · 1 March 2021IP consultancy partnership. Mr. Rainer Gunzelmann serves as honorary international chief IP consultant. Wuesthoff assists with global IP protection including EU, US markets and deepening global IP strategies.
• TAE Life SciencescoreTechnology or Integration · 9 December 2020Joint-Venture with TAE Life Sciences for NeuPex accelerator supply. TLS provided ~$10 million minority equity investment to Neuboron Therapy System (NTS). TLS provides vacuum insulated tandem accelerator for NeuPex, strengthening the supply chain for the AB-BNCT system and expanding global deployment capability.
• Xiamen Humanity HospitalflagshipStrategic or Co-development Partner · 1 May 2019Strategic partnership to build China's first BNCT Center at XHH (construction started May 2019, beam delivered August 2021). Center has two horizontal and one vertical treatment rooms, covering ~1,300 sqm. First BNCT clinical trials (IIT and IND registration trials) conducted at this center. Serves as international research harbor for BNCT collaboration.
• Peking Union Medical College HospitalcoreStrategic or Co-development Partner · 1 January 2019F-BPA clinical study conducted using nucleophilic radiosynthesis. Collaboration on NBB-002 companion diagnostic drug development with Director Huo Li. Part of Neuboron's clinical network for BNCT research.
• China Pharmaceutical UniversityminorStrategic or Co-development Partner · 1 January 2019Academic partnership for BNCT drug development and research, contributing to Neuboron's university collaboration network.
• Zhejiang UniversityminorStrategic or Co-development Partner · 1 January 2019Academic partnership contributing to Neuboron's BNCT university research ecosystem.
• Shanghai Renji HospitalminorStrategic or Co-development Partner · 1 January 2019Partnership established 2019 for BNCT facility development alongside the Shanghai-based hospital.
• Yantai Dongcheng Pharmaceutical GroupcoreStrategic or Co-development Partner · 1 January 2017Partnership for boron drug development. Yantai Dongcheng (now DC AMS PHARMA, MITRO Biotec) collaborated on preclinical research for 18F-BPA development.
• Nanjing University of Aeronautics and Astronautics (NUAA)coreStrategic or Co-development Partner · 1 January 2016Long-standing R&D partnership including joint talent cultivation, collaborative research, and industrial development. Joint National Key Project (China-Italy) granted 2016. Joint postdoctoral and research fellow positions at Xiamen BNCT Center. Prof. Tang Xiaobin from NUAA collaborates on BNCT. NUAA Department of Nuclear Science and Engineering co-organized 2018 International BNCT Development Forum.
• Italian National Institute of Nuclear Physics (INFN)coreStrategic or Co-development Partner · 1 January 2016Bilateral national key project collaboration. INFN-Pavia unit collaborates on neutron beam optimization, SPECT for real-time boron measurement, dose modeling, and Caserta BNCT project in Italy. Sino-Italian Fund AMONG-US program approved 2022. Neuboron provides guidance for Italy's first government-backed AB-BNCT project at Caserta.
• University of Pavia (Italy)coreStrategic or Co-development Partner · 1 January 2016Co-organized 2018 International BNCT Development Forum with NUAA. Prof. Saverio Altieri delivered opening speech. Ongoing collaboration on research fronts, clinical experience, and BNCT development trends.
• Budker Institute of Nuclear Physics (Russia)coreTechnology or Integration · 1 January 2016Collaboration leveraging BINP's merits in target design to jointly generate neutrons for NeuPex. Part of Neuboron's global BNCT ecosystem combining international expertise.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Novartis (Advanced Accelerator Applications): Through Pluvicto (lutetium-177 PSMA) and Lutathera, Novartis is the global leader in therapeutic radiopharmaceuticals. Comparable in theranostic strategy and boron-drug-style targeting approach, though focused on different radioisotopes and oncology indications.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals (e.g., Illuccix for PSMA-PET). Comparable as a theranostic-platform company targeting oncology, though focused on different isotopes and indications.
• Elekta: Major radiation therapy and radiosurgery equipment manufacturer (Leksell Gamma Knife, Versa HD linacs). Competes for hospital capital budgets that could alternatively be spent on BNCT systems.
• Brainlab: Provides radiation oncology treatment planning software and image-guided systems. Competes with NeuManta TPS in hospital software purchasing decisions, particularly for cranial and spine indications overlapping with glioblastoma BNCT use cases.
• Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology systems (linear accelerators, proton therapy, treatment planning). Represents the dominant incumbent that BNCT must displace or complement; offers broader portfolio but no BNCT-specific system.

Direct peers

• RaySearch Laboratories: Provides treatment planning systems (RayStation) used widely in radiation oncology. Competitor to Neuboron's NeuManta TPS across proton, photon, and emerging particle therapy modalities — directly competing for hospital software budgets.
• Sumitomo Heavy Industries: Develops and manufactures the NeuCure BNCT system, already approved and used clinically in Japan for recurrent head and neck cancer. The closest direct competitor to Neuboron's NeuPex, sharing accelerator-based BNCT architecture and targeting the same indications.
• Neutron Therapeutics: US-based company developing accelerator-based BNCT systems (nuBeam) for hospital deployment. Directly competes with Neuboron in international BNCT markets, particularly targeting North America and Europe.

Emerging players

• TAE Life Sciences: JV partner and minority equity holder in Neuboron Therapy System. Also develops accelerator-based BNCT systems in the US, making it both a partner and a partial competitor in the global BNCT landscape.
• ITM Isotope Technologies Munich: Develops and manufactures therapeutic and diagnostic radioisotopes (including lutetium-177 and actinium-225) for targeted radionuclide therapy. Comparable as a vertically integrated radiopharmaceutical platform targeting oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/neuboron-medtech-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuboron Medical Group